PP 007
Alternative Names: PP-007Latest Information Update: 11 Jan 2023
At a glance
- Originator Primary Peptides
- Class Antidementias; Peptides
- Mechanism of Action Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 10 Jan 2023 Preclinical trials in Amyotrophic lateral sclerosis in Canada (unspecified route) as of January 2023 (Primary Peptides pipeline, January 2023)
- 10 Jan 2023 Preclinical trials in Frontotemporal dementia in Canada (unspecified route) as of January 2023 (Primary Peptides pipeline, January 2023)
- 07 Jul 2021 Primary Peptides intends to submit patent for PP 007 (Primary Peptides website, July 20210